Resource Summary Report

Generated by NIF on Sep 11, 2026

Phospho-Akt (Thr308) (D25E6) XP® Rabbit mAb

RRID:AB_2629447
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 13038, RRID:AB_2629447

Antibody Information

URL: http://antibodyregistry.org/AB_2629447

Proper Citation: Cell Signaling Technology Cat# 13038, RRID:AB_2629447

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IF-IC, F

Antibody Name: Phospho-Akt (Thr308) (D25E6) XP® Rabbit mAb

Description: This monoclonal targets

Clone ID: Clone D25E6

Antibody ID: AB_2629447

Vendor: Cell Signaling Technology

Catalog Number: 13038

Record Creation Time: 20231110T034746+0000

Record Last Update: 20260829T171413+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Akt (Thr308) (D25E6) XP® Rabbit mAb.

No alerts have been found for Phospho-Akt (Thr308) (D25E6) XP® Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 163 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Long F, et al. (2026) MEDAG functions as an A-kinase-anchoring protein in adipocytes. Molecular cell, 86(5), 937.

Zhu Q, et al. (2026) Optogenetic control of plasma membrane O-GlcNAcylation regulates WNK1 condensates and cellular signaling. Cell chemical biology, 33(6), 862.

Zorn A, et al. (2026) The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells. British journal of pharmacology.

Chen J, et al. (2026) Upregulation of CENPM facilitates glioma progression via PI3K/AKT signaling pathway. Genomics, 118(1), 111163.

Pendyala S, et al. (2026) Image-based, pooled phenotyping reveals multidimensional, disease-specific variant effects. Cell, 189(13), 4040.

Meng F, et al. (2026) The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. Nature communications, 17(1), 614.

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. Cell reports. Medicine, 7(2), 102578.

Wetterwald L, et al. (2026) MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion. The Journal of experimental medicine, 223(5).

Park SJ, et al. (2026) Mechanism by which a linoleic acid metabolite suppresses cancer cell growth by inhibiting mTOR. Cell chemical biology, 33(5), 637.

Chen YL, et al. (2026) Endometrial stromal cell-derived TMAO sustains decidualization to prevent recurrent spontaneous abortion. Cell metabolism.

Li G, et al. (2026) Non-enzymatic ABHD6 interacts with Akt-FoxO1 axis to regulate selective hepatic insulin resistance. bioRxiv : the preprint server for biology.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. Cell reports, 45(4), 117198.

Powers J, et al. (2026) eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression. Cancer research.

Yu L, et al. (2026) Activin A enhances neurofunctional recovery following traumatic spinal cord injury by inhibiting autophagy. Neural regeneration research, 21(6), 2485.

Ma X, et al. (2026) UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma. Cell reports, 45(4), 117154.

Bai L, et al. (2026) AKT1 glutarylation regulated by GCDH and SIRT5 suppresses oncogenic signaling. Cell reports, 45(6), 117394.

Koundouros N, et al. (2025) Direct sensing of dietary ?-6 linoleic acid through FABP5-mTORC1 signaling. Science (New York, N.Y.), 387(6739), eadm9805.

Jin G, et al. (2025) Therapeutic management of PI3K? inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3K? inhibitor therapy. Molecular metabolism, 96, 102151.

Zhang Y, et al. (2025) Catenibacteriummitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid. Cell metabolism.

Smolag KI, et al. (2025) Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment. Cancer immunology research, 13(1), 122.